CD20-CD19 cCAR T cell therapy (iCell Gene Therapeutics)

N/A

Report date: 2024/01/02 20:03:52

Base Information

Drug NameCD20-CD19 cCAR T cell therapy (iCell Gene Therapeutics)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionT lymphocyte replacementsAnti-CD19Anti-CD20
TargetsB-lymphocyte antigen CD19B-lymphocyte antigen CD20
Therapy Area/IndicationsLymphoma, B-CellLeukemia, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaPending
Originator CompaniesIcell Gene Therapeutics (Int'L) Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesiCell Gene Therapeutics LLCiCar Bio Therapeutics Ltd
Active IndicationsN/A
Inactive IndicationsLymphoma, B-CellLeukemia, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A